Teams up with leading dermatologist

Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.

The agreement concerns the wound healing treatment Chronseal, a product jointly owned by Tripep and their japanese partner company Kringle Pharma. The letter of intent is signed with the japanese specialty pharma company Maruho, the largest dermatology company of Japan, granting them the rights to, as first company, evaluate the results from an on-going phase I/II study of Chronseal. The agreement also grants Maruho the rights to negotiate the sales rights for Chronseal on the Japanese market.

Two clinical pilot studies on Chronseal have been successfully conducted on a total of 24 patients with chronic leg ulcers. Tripep has recently started a multicenter phase I//II study.

Medlemsnytt

Se alla medlemsnyheter

Mest läst

Andra Nordiska Medier

Ja tack, jag vill gärna få Life Science Swedens nyhetsbrev Läs cookie- och datapolicy.

Ja tack, jag vill gärna få marknadsföring, erbjudanden, undersökningar o.s.v. från Life Science Sweden Läs cookie- och datapolicy.

Nyhetsbrev

Life Science Sweden Breaking/Extra

Life Science Sweden Eventnyheter

{{ visitor.ipAccess.member.name }}

{{ visitor.ipAccess.corporateClient.name }}

{{ visitor.user.name }}

Teams up with leading dermatologist

Medlemsnytt

Mest läst

Jobb i fokus

Senaste nytt

Utvalda artiklar

Utvalda nyheter från förstasidan

Forskningscenter stoppas på grund av brister – ”Väldigt allvarligt”

Moderna utökar samarbete med Open AI – växlar upp med artificiell intelligens

Positivt USA-besked för Medivir – ”Vi är mycket glada”

Vårdkonflikten rycker närmare – bara timmar återstår

Vd-byte på Dignitana

Andra Nordiska Medier

Nyhetsbrev

Sänd till en kollega